NCT05674539View on ClinicalTrials.gov

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Acute Myeloid Leukemia, AdultMyelodysplastic Syndrome(MDS)Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
DRUG

Fludarabine and Busulfan

Fludarabine with total dose of 150 mg/m\^2 in combination with Busulfan with total dose of 6.4 mg/kg

DRUG

Fludarabine and Melphalan

Fludarabine with total dose of 150 mg/m\^2 in combination with Melphalan with total dose of 140 mg/m\^2

Trial Locations (1)

430000

Wuhan Union Hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER